• Home
  • News
  • Contact

Rokote Laboratories Finland Ltd updates its vaccine to be more effective against new virus variants too

by Okapit | Jun 6, 2022 | Uncategorized

Rokote Laboratories Finland Ltd has decided to update its intranasal vaccine because the SARS-CoV-2 BA.4 and BA.5 virus variants have become more common. Therefore, the launch of the clinical trials will be moved to 2023. SARS-CoV-2 appears to be here to stay and able...
Next Entries »

Recent Posts

  • Terhi Reunama Appointed as Head of Clinical Trial Operations
  • Our Nasal COVID-19 Vaccine Moves to First Human Trials
  • Rokote Laboratories Finland Oy Submits First Clinical Trial Application
  • Rokote Laboratories Finland Oy Announces CEO Transition and Future Plans
  • Professor Seppo Ylä-Herttuala received the 2023 Outstanding Achievement Award from ESGCT

Recent Comments

No comments to show.

Rokote Laboratories Finland Oy

Company ID: 3155372-4
VAT: FI31553724

  • Follow
Invoicing details